HER2-overexpressing breast cancer : Interim PET after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment - IMT Atlantique Accéder directement au contenu
Communication Dans Un Congrès EANM 2013 : Annual Congress of the European Association of Nuclear Medicine Année : 2013

HER2-overexpressing breast cancer : Interim PET after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment

Résumé

Background:Pathologic complete response (pCR) to neoadjuvant treatment (NAT) is associated with improved survival of patients with HER2+ breast cancer. We investigated the ability of interim positron emission tomography (PET) regarding early prediction of pathology outcomes.Methods:During 61 months, consecutive patients with locally advanced or large HER2+ breast cancer patients without distant metastases were included. All patients received NAT with four cycles of epirubicin+cyclophosphamide, followed by four cycles of docetaxel+trastuzumab. 18F-fluorodeoxyglucose (18F-FDG)-PET/computed tomography (CT) was performed at baseline (PET1) and after two cycles of chemotherapy (PET2). Maximum standardised uptake values were measured in the primary tumour as well as in the axillary lymph nodes. The correlation between pathologic response and SUV parameters (SUVmax at PET1, PET2 and ΔSUVmax) was examined with the t-test. The predictive performance regarding the identification of non-responders was evaluated using receiver operating characteristics (ROC) analysis.Results:Thirty women were prospectively included and 60 PET/CT examination performed. At baseline, 22 patients had PET+ axilla and in nine of them 18F-FDG uptake was higher than in the primary tumour. At surgery, 14 patients (47%) showed residual tumour (non-pCR), whereas 16 (53%) reached pCR. Best prediction was obtained when considering the absolute residual SUVmax value at PET2 (AUC=0.91) vs 0.67 for SUVmax at PET1 and 0.86 for ΔSUVmax. The risk of non-pCR was 92.3% in patients with any site of residual uptake >3 at PET2, no matter whether in breast or axilla, vs 11.8% in patients with uptake 3 (P=0.0001). The sensitivity, specificity, PPV, NPV and overall accuracy of this cutoff were, respectively: 85.7%, 93.8%, 92.3%, 88.2% and 90%.Conclusion:The level of residual 18F-FDG uptake after two cycles of chemotherapy predicts residual disease at completion of NAT with chemotherapy+trastuzumab with high accuracy. Because many innovative therapeutic strategies are now available (e.g., addition of a second HER2-directed therapy or an antiangiogenic), early prediction of poor response is critical.British Journal of Cancer advance online publication, 13 August 2013; doi:10.1038/bjc.2013.469 www.bjcancer.com.
Fichier non déposé

Dates et versions

hal-00936187 , version 1 (24-01-2014)

Identifiants

Citer

David Groheux, Mathieu Hatt, Elif Hindie, Sylvie Giacchetti, Patricia de Cremoux, et al.. HER2-overexpressing breast cancer : Interim PET after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. EANM 2013 : Annual Congress of the European Association of Nuclear Medicine, Oct 2013, Lyon, France. ⟨10.1038/bjc⟩. ⟨hal-00936187⟩
56 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More